These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35563884)

  • 1. Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.
    Kasindi A; Fuchs DT; Koronyo Y; Rentsendorj A; Black KL; Koronyo-Hamaoui M
    Cells; 2022 May; 11(9):. PubMed ID: 35563884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer Acetate: from Bench to Bed and Back.
    Arnon R; Aharoni R
    Isr Med Assoc J; 2019 Mar; 21(3):151-157. PubMed ID: 30905097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.
    LoPresti P
    Neurochem Res; 2015 Mar; 40(3):473-9. PubMed ID: 25481047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evolving Mechanisms of Action of Glatiramer Acetate.
    Prod'homme T; Zamvil SS
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
    McKeage K
    CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis.
    Koc Ü; Haupeltshofer S; Klöster K; Demir S; Gold R; Faissner S
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831209
    [No Abstract]   [Full Text] [Related]  

  • 8. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D
    J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction in experimental autoimmune encephalomyelitis.
    Makar TK; Guda PR; Ray S; Andhavarapu S; Keledjian K; Gerzanich V; Simard JM; Nimmagadda VKC; Bever CT
    Sci Rep; 2023 Apr; 13(1):5635. PubMed ID: 37024509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enterococcus faecium strain L-3 and glatiramer acetate ameliorate experimental allergic encephalomyelitis in rats by affecting different populations of immune cells.
    Abdurasulova IN; Matsulevich AV; Tarasova EA; Kudryavtsev IV; Serebrjakova MK; Ermolenko EI; Bisaga GN; Klimenko VM; Suvorov AN
    Benef Microbes; 2016 Nov; 7(5):719-729. PubMed ID: 27633171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R; Sela M
    J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
    Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS.
    Hadidi N; Pazuki G
    Sci Rep; 2022 Dec; 12(1):22042. PubMed ID: 36543898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
    J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
    Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
    Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.